Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 16NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 49Prostatic Neoplasms 38Carcinoma, Non-Small-Cell Lung 28Neoplasms 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Multiple Myeloma 22Lymphoma 21Leukemia, Myeloid, Acute 17Colorectal Neoplasms 17Melanoma 15Lung Neoplasms 13Hodgkin Disease 11Brain Neoplasms 11Medulloblastoma 10Lymphoma, Non-Hodgkin 10HIV Infections 10Glioblastoma 10Squamous Cell Carcinoma of Head and Neck 9Pancreatic Neoplasms 9Neoplasm Metastasis 9Leukemia, Biphenotypic, Acute 9Leukemia 9Head and Neck Neoplasms 9Neuroblastoma 8Hematologic Neoplasms 8Ependymoma 8Glioma 7Carcinoma, Renal Cell 7Astrocytoma 7Wilms Tumor 6

Interventions

merphos 1imetelstat 1hydrocortisone hemisuccinate 1fludarabine 1Spinal Puncture 1Specimen Handling 1Methotrexate 1Leucovorin 1Hydrocortisone 1GRN163L peptide 1Cytarabine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Myelomonocytic, Juvenile × 1 year × Clear all
NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡